AMC Bio is developing a novel Precision Viral Persistence (PVP) test for Long COVID.

AMC Bio is a deep-tech pre-clinical stage company developing novel 1st in Class diagnostics and therapeutics, including a ground-breaking Long COVID diagnostic and two preclinical programs - both synthetic peptides and a bacterial polypeptide effective against Dengue, COVID, and other RNA viruses that account for nearly half of emerging contagious diseases. Our team includes seasoned biopharma executives Susan K. Finston, Founder and President, Pascal Neuville, GM, and, as Strategic Advisor, Christian Policard, and, as Scientific and Clinical Advisor, Prof. Edouard Tuaillon, MD, Head of Virology, CHU Montpellier, France. The COVID pandemic has opened a Pandora’s Box of RNA viral pathogens – including Long COVID, Dengue Fever – the most dangerous of mosquito-borne (“arbovirus”) diseases – Chikungunya, West Nile and Zika. For millions of patients struggling with symptoms years after acute COVID infection, lack of science-backed tests for Long COVID complicates diagnosis and treatment. There are currently no therapeutic treatments available for Dengue Fever and other arboviruses – and growing numbers of Western Patients will demand treatment.

Founded 2024